IQVIA Holdings, Inc. Common Stock (IQV)

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune® World’s Most Admired Companies™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights, and healthcare intelligence, today announced a strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences.

Despite a drop in venture funding for digital health companies over the last two-and-a-half years, digital health products and solutions are expanding in scope and function to aid patient diagnosis, treatment, and monitoring. More solutions are now focused on specific diseases, and their commercial appeal has grown as developers build solutions that bring value back to providers, are more easily integrated with health systems, and embrace innovation such as AI to personalize care and reduce provider workload. Product types have also expanded, with health assessment tools such as digital diagnostics, sensor-based digital measures, and remote patient monitoring solutions joining digital therapeutics and consumer health apps to offer value for personal health and clinical care. These findings are based on a new report from the IQVIA Institute for Human Data Science: Digital Health Trends 2024: Implications for Research and Patient Care.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS Healthcare Conference in Rancho Palos Verdes, California on Wednesday, November 13, 2024 at 1:15 p.m. ET.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2024.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA (NYSEIQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights.

IQVIA™ (NYSEIQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in New York on Wednesday, September 4, 2024 at 10:00 a.m. ET.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQRXRX),NASDAQ:EXAINASDAQEXAI)(NASDAQ:TWSTNASDAQTWST,(NYSE:IQVNYSE) EQNX::TICKER_END

PALM BEACH, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards the potential of generative AI in healthcare. In order to safely bring AI into the healthcare space, state governments across the USA are working on how to regulate its implementation. The potential to enhance accuracy and speed in diagnostics, analyzing eye scans and predicting complications, and even designing new drugs, the potential for AI in healthcare is too big to ignore. Reaching the goal of safely bringing AI into the medical space still requires lots of research and development, with several tech innovators recently updating the market with their latest developments, including: Avant Technologies Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQRXRX), Exscientia plc NASDAQ: EXAINASDAQEXAI)(NASDAQ: TWSTNASDAQTWST and IQVIA Holdings Inc. (NYSE: IQVNYSE).

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended June 30, 2024.

IQVIA™ (NYSEIQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA™ (NYSEIQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the “Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards.

IQVIA (NYSEIQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.

As cancer incidence continues to rise, it’s being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, “Global Oncology Trends 2024: Outlook to 2028.”

Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Bank of America Health Care Conference in Las Vegas on Tuesday, May 14, 2024 at 12:20 p.m. ET (9:20 a.m. local PT).

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024.

IQVIA (NYSEIQV) today announced that Wendy Stewart, president of Clinical Operations at IQVIA, and Susan Barnes, senior director of IQVIA Biotech Strategic Operations, have been honored with the Healthcare Businesswoman's Association Luminary and Rising Star Awards, respectively.

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.

IQVIA (NYSEIQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce NYSE:CRMNYSECRM)

IQVIA Holdings Inc. (“IQVIA”) (NYSEIQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024 at 9:30 a.m. ET.